Aiping Zhou

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang et al. · Clinical Cancer Research · 2020 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

Dingwei Ye, Jiyan Liu, Aiping Zhou et al. · Cancer Science · 2020 · 116 citations · Full text

Life Sciences, Immunology, Oncology +17

Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial

Aiping Zhou, Yuxian Bai, Yan Song et al. · The Oncologist · 2019 · 115 citations · Full text

Medicine, Oncology, Pharmacology +12

Application of¹H NMR Spectroscopy-Based Metabolomics to Sera of Tuberculosis Patients

Aiping Zhou, Jinjing Ni, Zhihong Xu et al. · Journal of Proteome Research · 2013 · 94 citations

Life Sciences, Biochemistry, Clinical Biochemistry +16

Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study

Xiaoqing Yan, Ming Ye, Qing Zou et al. · Annals of Oncology · 2023 · 75 citations · Full text

Medicine, Oncology, Pharmacology +13